Microba Life Sciences Limited (MAP.AX)
AUD 0.19
(0.0%)
AUD 0.19
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | -8.58 Million AUD | -26.71% |
| 2023 | -6.77 Million AUD | -386.3% |
| 2022 | 2.36 Million AUD | 144.6% |
| 2021 | -5.3 Million AUD | -30.89% |
| 2020 | -4.05 Million AUD | -62.76% |
| 2019 | -2.49 Million AUD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -4.4 Million AUD | -728.67% |
| 2024 FY | -8.58 Million AUD | -26.71% |
| 2024 Q1 | 700.93 Thousand AUD | 121.07% |
| 2024 Q4 | -4.17 Million AUD | 0.0% |
| 2023 Q1 | 517.57 Thousand AUD | 111.95% |
| 2023 Q4 | -3.32 Million AUD | -504.97% |
| 2023 FY | -6.77 Million AUD | -386.3% |
| 2023 Q3 | 821.56 Thousand AUD | 123.84% |
| 2023 Q2 | -3.44 Million AUD | -765.77% |
| 2022 Q1 | 586.38 Thousand AUD | 119.51% |
| 2022 Q4 | -4.33 Million AUD | -826.25% |
| 2022 FY | 2.36 Million AUD | 144.6% |
| 2022 Q3 | 596.46 Thousand AUD | 117.45% |
| 2022 Q2 | -3.41 Million AUD | -682.93% |
| 2021 Q3 | 571.13 Thousand AUD | 124.84% |
| 2021 FY | -5.3 Million AUD | -30.89% |
| 2021 Q4 | -3 Million AUD | -626.23% |
| 2021 Q2 | -2.29 Million AUD | -613.3% |
| 2021 Q1 | 447.92 Thousand AUD | 0.0% |
| 2020 FY | -4.05 Million AUD | -62.76% |
| 2019 FY | -2.49 Million AUD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Australian Clinical Labs Limited | 247.36 Million AUD | 103.47% |
| BCAL Diagnostics Limited | 3.09 Million AUD | 377.015% |
| Genetic Signatures Limited | -16.2 Million AUD | 47.027% |
| Genetic Technologies Limited | 3.9 Million AUD | 319.804% |
| Healius Limited | 541.2 Million AUD | 101.586% |
| Imagion Biosystems Limited | -3.88 Million AUD | -121.013% |
| Integral Diagnostics Limited | 103.8 Million AUD | 108.268% |
| INOVIQ Ltd | -989.82 Thousand AUD | -767.045% |
| Monash IVF Group Limited | 85.5 Million AUD | 110.038% |
| Rhythm Biosciences Limited | -1.35 Million AUD | -532.266% |
| Sonic Healthcare Limited | 2.33 Billion AUD | 100.368% |